May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Insights from GUtrends25 on Urothelial Cancer Treatment by Tom Powles
Mar 31, 2025, 18:51

Insights from GUtrends25 on Urothelial Cancer Treatment by Tom Powles

Tom Powles, Professor at the University of London, shared a post on X:

“At GUtrends25 we compared EV, SG, Erda(FGFR +ves), taxane +/- ramucirumab (VEGFR mAB) in pretreated urothelial cancer. The control arms performed similarly. EV & Erda (FGFR+) look quite similar, but SG slightly less activity & tox. Ram got PFS but no OS, halting VEGF in UC.

This is a suboptimal place to test drugs due to resistance/tox/ OS. Some good drugs may have been lost (potentially such as SG or RAM). Future studies will have different patient characteristics due to prior EVP. Activity post EVP is not necessarily the same so we start again.”

Insights from GUtrends25 on Urothelial Cancer Treatment by Tom Powles

More posts featuring Tom Powles.